CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects.
about
Cardiac safety of ophthalmic timolol.CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese PopulationIdiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.From pharmacogenetics to imaging pharmacogenetics: elucidating mechanisms of antidepressant response.
P2860
CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
CYP2D6 and pharmacogenomics: w ...... cus? Part 2: clinical aspects.
@en
CYP2D6 and pharmacogenomics: w ...... cus? Part 2: clinical aspects.
@nl
type
label
CYP2D6 and pharmacogenomics: w ...... cus? Part 2: clinical aspects.
@en
CYP2D6 and pharmacogenomics: w ...... cus? Part 2: clinical aspects.
@nl
prefLabel
CYP2D6 and pharmacogenomics: w ...... cus? Part 2: clinical aspects.
@en
CYP2D6 and pharmacogenomics: w ...... cus? Part 2: clinical aspects.
@nl
P2860
P356
P1433
P1476
CYP2D6 and pharmacogenomics: w ...... cus? Part 2: clinical aspects.
@en
P2093
Andrea Gaedigk
J Steven Leeder
P2860
P304
P356
10.2217/PGS.14.27
P577
2014-06-01T00:00:00Z